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Two Good Clinical Practice studies are described. Firstly, the safety and efficacy of live, attenuated LaSota and 
l-2 Newcastle Disease (ND) vaccines and inactivated, adjuvanted ITA-NEW ND vaccine were evaluated in eight-
day old local ecotype chicks. For all vaccines safety and efficacy were satisfactory and serological titres 
exceeded the putative protective level of >2
3 
before 14 days post-vaccination. The vaccinated groups displayed 
no significant differences. The data suggest that these vaccines are effective in very young village poultry. 
Secondly, in 35 day-old ISA-Brown pullets, MSD a 10x field dose formulation of Clone 30 vaccine, was 
compared to I-2 after a heat-stress test approximating to local conditions of delivery and use (24h, 32.3
o
C, in the 
dark). By 14 days post-vaccination, the heated MSD vaccine and heated I-2 titres exceeded 2
3 
but the response 
of the heated MSD group was significantly higher than the heated I-2 group. Non-heated MSD induced a very 
rapid and higher response than those induced by the heated vaccines, as by 7 days post-vaccination, a 2
3 
titre 
was reached and exceeded (GMT 4.0). The 10x normal field dose approach to conferring thermotolerance to live 
vaccines appears to be a simple, cheap and pragmatic method for use in hot climates. 
 
Keywords: Newcastle Disease vaccines, agricultural development, thermotolerance, LaSota, I-2, ITA-NEW, Clone 30. 
 
 
INTRODUCTION 
 
Approximately 70% of Africa’s chickens, comprising 
some 1.5 billion birds (FAO 2007), are multi-age village 
or backyard chickens of local ecotypes with unknown 
genetics (Sector 4, FAO 2007). These birds act as food  
 
 
*Corresponding author E-mail: gildomingue@yahoo.co.uk 
Tel: +44798 969 3103.  
security and also may provide cash income for poor rural 
households especially women, so enabling the purchase 
of household and other extra items such as children’s 
school accessories (Alexander et al., 2004; Perry et al., 
2002; Peters et al., 2012a, b;).  The most serious disease 
threat to these village chickens is Newcastle Disease 
(ND). This is due to its endemicity and mortality rates that 
can approach 100%. In addition to its severe impact on
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the rural poor, ND impacts national economies due to trade 
restrictions and embargoes (FAO/IAEA 2004, Alexander and 
Senne, 2008; GALVmed, PANVAC and IIAM Conference, 
2009). ND can be controlled and prevented by routine 
vaccination using live attenuated or  inactivated vaccines 
(OIE, 2013) but in the developing world there is insufficient 
routine husbandry or disease control for village chickens 
(Alexander and Senne, 2008; Tirunesh and Gerima, 2016). 
In reality, livestock health is often overlooked despite it being 
a powerful socio-economic driver 
(http://www.onehealthinitiative.com; One Health Initiative, 
The World Bank, 2010).  
GALVmed (Global Alliance for Livestock Veterinary 
Medicines; www.galvmed.org) is a not-for-profit organisation 
which aims to improve socio-economic conditions by 
enhancing the availability of livestock medicines in markets 
that are unattractive to the global animal health industry. An 
important component of this aim is to develop technical 
partnerships with regional veterinary laboratories and here 
ND was identified as a priority disease for GALVmed to work 
on. This was because despite several vaccines being 
available there were few data obtained under controlled 
conditions suitable for registration dossiers in two vital areas: 
vaccine safety and efficacy in very young backyard chicks 
and vaccine thermotolerance which is a major need for 
effective ND and other veterinary vaccines in hot climates to 
reduce dependence upon a ‘cold chain’. 
One ND vaccine that has been employed in the field uses 
the I-2 strain which is naturally attenuated (sequencing 
indicated its avirulent status: 
112
R-K-Q-G-R--L-I-G
119
; 
Wambura et al. 2007) and is also naturally thermotolerant 
(Australian Centre for International Agricultural Research, 
ACIAR; 2002). The I-2 master seed was made freely 
available to developing countries by ACIAR but it was not 
formally registered in these countries. GALVmed was asked 
to take pro-poor action by obtaining Good Clinical Practice 
(GCP) standard data (EC Europa 1991, VICH 2000) and 
preparing an I-2 Registration Dossier that would be placed 
into AU-PANVAC ownership. For the thermotolerance 
investigations, some commercial ND vaccines were 
available but their properties under controlled conditions 
suitable for registration were unclear. However, a 10x 
formulation of Clone 30 ND vaccine did become available for 
study. So two completely separate studies to evaluate 
available vaccine candidates were implemented to GCP 
standard, one for their safety and efficacy in very young 
chicks and the other to evaluate some vaccines for their 
thermotolerance. 
 
MATERIALS AND METHODS 
 
Studies 
 
Two separate GCP standard studies were conducted with 
the collaborating laboratories receiving appropriate 
training from GALVmed before commencement. The first 
study used 8-day old backyard chicks and evaluated the 
ability of three ND vaccine formulations to induce 
protective antibodies. The second study used 35 day 
commercial birds and was carried out to assess 
protection against challenge from two live, attenuated 
vaccines that had been pre-heated (see below) to 
simulate conditions of transport and field use, before 
reconstitution, titration and vaccination. The parallel 
group design flows for the studies are shown in Figure 1A 
and 1B.  
 
Birds 
 
The first study was carried out at Sokoine University of 
Agriculture (SUA), Sokoine, Tanazania and used 
backyard (i.e. unknown genetics) male and female day-
old chicks sourced from a local commercial hatchery’s 
minimum disease layer flock that was negative for ND 
virus antibody. For study 2 carried out at the Kenya 
Veterinary Vaccine Production Institute (KEVEVAPI), 
Nairobi, Kenya, new-born ISA-Brown female chicks 
(Sigma Ltd, Kenya) were reared in an on-site Brooder 
House for 35 days to allow decay of any maternal ND 
antibodies. All birds were given feed and water ad libitum 
throughout the studies.  
 
Randomisation  
 
After confirmation of seronegativity (i.e. undetectable ND 
antibodies; see Haemagglutination Inhibition below), 
birds in both studies were fitted with numbered leg rings 
(Roxan Developments Ltd, Selkirk, Scotland).  The rings 
had earlier been randomly allocated to treatments on a 
blinded basis.  For study 1, seven day old chicks were 
randomly allocated into four treatment groups of 50 per 
group. For study 2, 33 day old pullets were randomly 
allocated to three treatment groups of 50 birds per group. 
All birds were observed frequently throughout both 
studies for general health (EC Europa, 1991).  More 
detailed clinical examinations were carried out around the 
time of vaccination (Figure1A and 1B). 
 
Vaccines, vaccination and heat treatment 
 
The vaccines in study 1 (see Table) were a commercial, 
locally available, attenuated LaSota vaccine (V1.1; Shafit 
Labs Ltd, Israel) a locally produced I-2 vaccine originally 
from ACIAR master seed (V1.2; Central Veterinary 
Laboratory, CVL, Temeke, Tanzania) and an adjuvanted, 
inactivated, thermotolerant vaccine (V1.3; ITA-NEW; 
Laprovet, France).  
In study 2, the commercial ND Clone 30 vaccine supplied 
at 10 times the registered dose (MSD vaccine, MSD, The 
Netherlands) was used as a control (V2.1; see Table)
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Figure 1 A. Study 1 parallel flow study design (N.B. post-treatment days are grouped by daily activity; D, Study Day). 
 
 
     
     
 
 
 
 
 
 
Figure 1B. Study 2 parallel flow study design (N.B. post-treatment days are grouped by daily activity; D, Study Day). 
 
 
 
 
 
1, Clinical examination; 2, Haemagglutination Inhibition titres; 3, Study Day; 4, Phosphate buffered saline, pH 7.4; 5, Clinical examinations post-vaccination; 6, Daily General Health Observations; 7, Heated (24h at 
32.3
o
C in the dark). 
 
 
 
and when pre-heated (V2.2) as below. Another I-2 
vaccine also from ACIAR master seed (KEVEVAPI) was 
used when pre-heated (V2.3) as below. All vaccines 
were titrated in duplicate before use and were 
administered within two hours of reconstitution. In study 
1 all vaccines were used without prior heat treatment. In 
study 2 some MSD vials and all the I-2 vials were heat-
stressed in the dark for 24h at 32.3
o
C (Avt temperature 
logger; Comark, England) before reconstitution and use. 
Chick arrival 
Clin.exam.dailyfor  7 
days then once 
weekly with DGHOs
6
 
on the other week 
days, to 32 days 
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Page 4 of 8 
 
Domingue et al.          180 
 
 
Table. Details of vaccines used in the two studies. 
 
Stud
y 
Site Vaccine
1
 
Vaccine 
identity 
Vaccine 
manufacture
r 
Numbe
r of 
birds 
Age at 
vaccinatio
n (days) 
Volume and 
route of 
vaccination
1
 
Active 
componen
t per vial
2
 
1 SUA V1.1 LaSota strain Shafit Labs, 
Israel 
50 8 20µl IO >10
8 
EID50 
V1.2 I-2 CVL, 
Temeke, 
Tanzania 
50 8 20µl IO >10
8 
EID50 
V1.3 ITA-NEW Laprovet, 
France 
50 8 200µl IM >10
8 
EID50 
V1.4 PBS control  PBS 50 8 20µl IO Not 
applicable 
2 KEVAVAP
I 
V2.1 Non-heated 
Clone 30 
MSD 50 35 50µl IO >10
9 
EID50 
V2.2 Heated
3
Clon
e 30 
MSD 50 35 50µl IO 10
6
 EID50 
V2.3 Heated
3
 I-2 KEVAVAPI 50 35 50µl IO 10
6
 EID50 
V2.4 PBS control KEVAVAPI 50 35 50µl IO NA 
 
1 = IO, intra-ocular; IM, intra-muscular 
2 = vaccines were reconstituted and administered according to the manufacturer’s instructions. They were titrated before administration. 
3 = 24h at 32.3
o
C in the dark before reconstitution and titration; titre drops of 3 log and 2 log for MSD and I-2 respectively to10
6
 EID50 per vial for both 
were noted. 
 
 
 
Sampling 
 
Before study 1 started, 10 four day old chicks were 
randomly selected, sacrificed and their blood sampled to 
confirm naïve serological status to NDV. Study birds were 
then bled (jugular vein) for baseline values on study day 
3, i.e. at randomisation and 24h before treatment, and 
then post-treatment bled weekly to 28 days (Figure 1A).  
In study 2, when the birds were 21 days old, 20 birds 
were randomly selected and bled from the ulnar vein to 
confirm naïve serological status to ND virus. This was 
repeated a week later with 20 different birds. Finally all 
birds were bled for baseline values 24h after 
randomisation (day 2; i.e. 24h before treatment), then 
after treatment bled weekly from weeks 1 to 5, then bled 
at two-weekly intervals from 7 weeks to 11 weeks (Figure 
1B). 
 
Haemagglutination Inhibition (HAI) titres 
 
In both studies, post-treatment sera were stored at -20
o
C 
and analyses carried out only after the end of the in-life 
phases to reduce variation. NDV antibody titres were 
determined by haemagglutination inhibition (HAI) in study 1 
according to Allan & Gough (1974) and in study 2 according 
to ACIAR (2002). Both studies used 25µl containing 4 
haemagglutinating units of ND strain V4 antigen. Fresh red 
blood cells were collected from NDV-free birds, pooled and 
thoroughly washed as described in the methods cited above. 
HAI tests always incorporated External Quality Assurance, 
EQA, samples. 
 
Statistical analysis 
 
In study 1, Geometric Mean Titres (GMTs; log2), were 
produced from the raw HAI data and analysed using one-
way ANOVA. Differences among treatment means were 
compared using Fisher's Protected Least Significant 
Difference test, PLSD, at a 5% probability (StatView
®
). In 
study 2, due to the study design, GMTs for the treatment 
groups and for individual bird titres were compared for 
differences using Tukey’s pair-wise comparison test. 
Differences in mean values were considered statistically 
significant at the 5% level. 
 
 
RESULTS AND DISCUSSION 
 
In both studies all pre-study and baseline sera samples were 
negative for NDV antibodies.There were no mortalities or 
local or systemic reactions following vaccination in any 
vaccinated groups indicating that all vaccines were safe 
when used under these conditions.  
Herd immunity, HI, (Diekmann and Heesterbeek 2000) is 
achieved if a fraction of birds with a high level of 
protection is equal to or greater than a certain critical
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Figure 2A. Study 1 HAI GMTs Induced by the Three ND Vaccines in 8 day old chicks (+ standard error; D, Study Day; Rx, treatment). 
 
 
 
 
fraction of potential host birds. For ND, a high level of 
protection in the HAI test is defined as a log2 titre >2
3 
or a 
GMT > 3.0 (ACIAR, 2002, Allan and Gough, 1974, van 
Boven et al., 2008). This interpretation was used in our 
studies, i.e. HI would be achieved if > 85% of target birds, 
the critical fraction, had a GMT > 3.0 (van Boven et al., 
2008). 
The first study was carried out as although several ND 
vaccines brands are available in east Africa, there was a 
seeming lack of GCP standard data on the safety and 
efficacy of the main candidates likely to be used in very 
young village chicks. Here, birds were not challenged 
with live virus for ethical reasons. Instead the serological 
response was used as a marker of immunogenicity. 
Mean antibody titres for the three vaccinated groups are 
shown in Figure 2A.  After vaccination NDV antibody 
levels increased significantly in all three groups by Study 
Day 11, D11 (i.e. 7 days post-vaccination) and by D18 
they had exceeded the protective level of 2
3
. Peak mean 
GMTs were obtained for all vaccines at D32. There were 
no significant differences in response between the three 
vaccine groups, but all vaccinated groups showed 
significant differences (P<0.001) from the negative 
control group. The duration of immunity, DOI (the time 
during which HAI titres >2
3
 are sustained) in this short 
study for all vaccines was from before D18 to study end. 
The IO route of administration was used for the 
attenuated LaSota and I-2 (and MSD in study 2) as this is 
the standard approach with live attenuated ND vaccines. 
It seems that IO is equivalent to other routes due to the 
close proximity to the Harderian gland, which has a role 
in immunity at the mucosal or secretory level (Alders et 
al. 2009; Degefa et al., 2004; Illango et al. 2008).  The 
ITA-NEW vaccine being an inactivated, adjuvanted 
vaccine was administered by IM injection.  The results of 
this GCP standard study which used very young 
backyard chicks with undetermined genetics, compared 
well to results published for LaSota (Awa et al. 2009; 
Degefa et al. 2004; Illango et al., 2008), for I-2 (ACIAR 
2002, Alders et al. 2009; Illango et al., 2008; Wambura et 
al. 2006) and for ITA-NEW (Bennejean et al. 1978; Dossa 
et al. 2005; Magand, 2009). Further work here could 
include a challenge phase. 
Study 2 evaluated thermotolerant properties i.e. the 
resultant immunogenicity after heat stress of the MSD 
and KEVEVAPI-produced I-2 vaccines. I-2 is considered 
a thermotolerant strain (ACIAR 2002) but for vaccine 
registration purposes, there were few controlled data on 
its protection against challenge after being heat stressed. 
Titration revealed that pre-heating before reconstitution 
for 24h at 32.3
o
C in the dark (conditions representative of 
field conditions), had caused drops in titre of 3 log and 2 
log for MSD and I-2 respectively to10
6
 EID50 per vial. 
Titres for all vaccinated groups reached >2
3 
by D17
0.00
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2.00
3.00
4.00
5.00
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Figure 2B. Study 2 HAI GMTs Induced by the Two ND vaccines in 35 day old pullets (+ standard error; D, Study Day; Rx, treatment). 
 
 
 
 
(Figure 2B) but in the non-pre-heated MSD group (V2.1) 
this was achieved surprisingly early by Study Day 10, 
D10 (i.e. by 7 days post-vaccination) which was also 
when the group’s peak GMT was reached. The peak 
GMTs for heated MSD and heated I-2 were detected at 
D17 and lasted to D31. The DOI for heated MSD was 
from before D17 to just before D52, c.f. that for heated I-2 
which was from before D17 to just after D38. Generally 
titres began to decline for the heated vaccine groups after 
D38 and with minor differences in titre between them. 
The non-pre-heated MSD appeared to induce a slower 
decline after peak concentrations had been reached and 
its DOI was from before D10 to just after D52.  
The term "thermotolerant" and not "thermostable" or 
"heat-resistant" is preferred by the authors in recognition 
that any vaccine has its heat tolerance limits. These 
relate to the local conditions of transport and use (ACIAR, 
2002; GALVmed, PANVAC and IIAM Conference, 2009). 
It was hypothesised that if the MSD vaccine was used, it 
would retain sufficient potency to be protective, even after 
the type of heat stress seen in the field, and that use at 
this dose could still be cost effective.  The data for I-2 
closely matched previous in-house results (KEVEVAPI) 
and the data upon the effects of temperature upon 
infectivity and immunogenicity from non-GCP standard 
studies (ACIAR 2002; Wambura et al. 2006). The data for 
the MSD vaccine are novel as there are no published 
GCP standard results for a 10x concentrated Clone 30 
and heat-stressing as implemented here (D. Goovaerts, 
MSD, The Netherlands, individual communication). Using 
a 10x field dose to offset a heat-induced drop in titre was 
effective as the heated vaccine still elicited satisfactory 
serological responses. The results were also consistent 
with other Clone 30 data (Rahman et al., 2002; van Eck 
and Goren, 1991; D. Goovaerts, MSD, The Netherlands, 
individual communication). Since the antigen used to 
determine the HAI titres was derived from the V4 virus, 
which is a virus closely related to the I-2 strain, HAI titres 
in the test could possibly be slightly artificially higher in 
favour of the I-2 vaccinated chickens. Nevertheless titres 
found in the MSD vaccinated groups were slightly higher 
compared to the I-2 vaccinated groups, indicating the 
good immunogenicity of this vaccine including in the heat 
treatment group. It was clear that heat treatment had a 
negative effect but the vaccines still showed good 
evidence of potency. Serological titres in all groups had 
declined to about 2 log2 by D80 (77 days post-vaccination 
suggesting that the putative Duration of Immunity, DOI, 
induced by these vaccines is relatively short in practical 
terms, which has implications for control programmes. 
However, the DOI is based not only on titre values but on 
protection in challenge experiments, and is likely to be 
longer due to mucosally-based protection even in the 
apparent absence of titres (D. Goovaerts, MSD, The 
Netherlands, individual communication). Clearly the 
safety and efficacy of the MSD vaccine may need further 
study especially if very young local ecotype chicks were 
to be considered. 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
D2 D10 D17 D24 D31 D38 D52 D66 D80
G
e
o
m
e
tr
ic
 M
e
a
n
 T
it
re
 (
lo
g
2
H
A
I)
Study Day
Control
Non-heated MSD
Heated MSD
Heated I-2
Rx, D3 
Protective titre/ Onset of Immunity: >3.0 
  
Page 7 of 8 
 
183         Afr. J. Poult. Farming 
 
 
 
However, Clone 30 is acknowledged to be safe (Rahman 
et al., 2002; van Eck and Goren, 1991) even at titres far 
exceeding the normal 10
6
 EID50 dose (D.Goovaerts, 
MSD, The Netherlands, individual communication). If the 
10x field dose approach to counteract thermolability in 
the field can be confirmed in larger GCP-standard trials 
incorporating a challenge phase, it may represent a 
simple, cheap, and pragmatic approach to the increased 
availability of quality vaccines made and produced to 
Good Manufacturing Practice standards in hot climates. 
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